Sarmayacar

Sarmayacar is Pakistan’s premier venture capital fund, founded in 2016 in Lahore and aggressively backing scalable technology models that digitize fragmented Pakistani industries. Healthcare is a real thesis area, with documented investments in Oladoc (a doctor-booking and telemedicine platform that has served over 15 million patients across a network of 25,000+ verified doctors) and Dawaai (an online pharmacy operating across Pakistan’s $3 billion pharmaceutical market). Check sizes of $1M to $5M place the firm in the meat of Pakistani seed and Series A activity.

The firm’s natural fit is with Pakistani founders building tech-enabled platforms in massive, fragmented sectors, including healthcare, fintech, mobility, and commerce. For healthcare founders specifically, the right profile is a team with credible local operational experience or a Pakistani technical founder building software, marketplace, or care delivery models targeting the country’s 240 million-plus population. The firm is AI-thematic but the deeper pattern is digitization of analog industries; AI is a tool, not the core thesis. Founders building deep biotech or clinical assets requiring multi-year patient capital are not the right fit.

Geographically, Sarmayacar’s advantage is unmatched in the Pakistani ecosystem: deep local network, regulatory familiarity, and credibility with international co-investors who want exposure to the market but lack local sourcing. For founders building primarily for the Pakistani diaspora or for cross-border GCC markets, the firm can be a useful regional anchor. For founders without Pakistan ties, the firm is not the natural partner.

The right entry path is a warm intro from a portfolio founder (Oladoc, Dawaai, Bazaar, etc.) or from a Pakistani diaspora operator with credibility in the firm’s network. The firm reads partner-led decks and responds to clear regional theses with strong unit economics. The pitch should lead with the Pakistani market wedge, evidence of product-market fit, and a credible follow-on plan that addresses the realities of cross-border capital from GCC or US investors. Healthcare-specific pitches should include a clear view on Pakistani payer dynamics, regulatory pathways, and the formal-informal market split.

Caveats. Pakistan’s macroeconomic and FX volatility introduces real risk into venture economics; cross-border holding structures matter. The firm’s healthcare-specific portfolio is concentrated in two large bets (Oladoc, Dawaai); if you are competing directly with either, expect a conflict-of-interest filter. Confirm the firm’s current deployment pace and follow-on appetite via reference calls with portfolio founders. For Pakistani healthcare founders building scalable digital platforms, Sarmayacar is the most credible domestic seed partner available; for non-Pakistani founders or deep clinical plays, look elsewhere.